TY  - GEN
AU  - Cahir-McFarland,Ellen
AU  - Ransohoff,Richard M
AU  - Lieberman,Linda
AU  - Plavina,Tatiana
TI  - CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response
SN  - 1526-632X
PY  - 0000///082016///
PB  - Neurology
N1  - Publication Type: Journal Article; Comment
UR  - https://doi.org/10.​1212/​01.​wnl.​0000496643.​57775.​41
ER  -